Функциональная гетерогенность фактора фон Виллебранда: патогенетическое значение и практические аспекты использования в кардиологии
Аннотация
Обзорная статья посвящена описанию участия фактора фон Виллебранда (ФВ), играющего важную роль в тромбообразовании при повреждении сосудов, в патогенезе сердечно-сосудистой патологии, обусловленной атеросклерозом. Избыточное образование и дисфункция ФВ, приводящие к внутрисосудистому тромбозу, способствует развитию дисфункции эндотелия, сосудистого воспаления, и, как следствие, инициации и прогрессированию атеросклероза. В обзоре представлена информация, основанная на анализе полнотекстовых публикаций в сервисе PubMed, содержащих данные о роли ФВ в развитии атеросклероза и его осложнений, а также о потенциальных возможностях влияния на этот показатель.
Ключевые слова
Об авторах
И. В. Алексеева
Курортная кардиологическая клиника «Чёрная Речка»
Россия
Россия
Руководитель диагностического центра
Санкт-Петербург, Россия
С. А. Уразгильдеева
Научно-клинический и образовательный Центр «Кардиология» медицинского факультета ФГБОУВО «Санкт-Петербургский государственный университет»
Россия
Россия
в.н.с. отдела атеросклероза научно-клинического и образовательного Центра «Кардиология», руководитель центра клинической липидологии и атеросклероза "Чёрная речка"
Санкт-Петербург, Россия
Список литературы
1. Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nature Reviews Cardiology. 2018;15(4):230– 40. DOI: 10.1038/nrcardio.2017.154
2. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204–22. DOI: 10.1016/S0140-6736(20)30925-9
3. Wu MD, Atkinson TM, Lindner JR. Platelets and von Willebrand factor in atherogenesis. Blood. 2017;129(11):1415–9. DOI: 10.1182/blood-2016-07-692673
4. Cucuianu M, Cucuianu A. Von Willebrand factor and cardiovascular disease. Restricted relevance. Romanian Journal of Internal Medicine. 2006;44(1):3–15. PMID: 17236283
5. Blann AD, McCollum CN. von Willebrand factor, endothelial cell damage and atherosclerosis. European Journal of Vascular Surgery. 1994;8(1):10–5. DOI: 10.1016/S0950-821X(05)80112-4
6. Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018;132(2):141–7. DOI: 10.1182/blood-2018-02-769000
7. Romani de Wit T, van Mourik JA. Biosynthesis, processing and secretion of von Willebrand factor: biological implications. Best Practice & Research Clinical Haematology. 2001;14(2):241–55. DOI: 10.1053/beha.2001.0132
8. Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators of Inflammation. 2017;2017:5620314. DOI: 10.1155/2017/5620314
9. Ruggeri ZM. Von Willebrand factor, platelets and endothel al cell interactions. Journal of Thrombosis and Haemostasis. 2003;1(7):1335– 42. DOI: 10.1046/j.1538-7836.2003.00260.x
10. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Practice & Research Clinical Haematology. 2001;14(2):257–79. DOI: 10.1053/beha.2001.0133
11. Wagner DD, Bonfanti R. Von Willebrand Factor and the Endothelium. Mayo Clinic Proceedings. 1991;66(6):621–7. DOI: 10.1016/S0025- 6196(12)60522-9 12. Ward SE, O’Sullivan JM, O’Donnell JS. The relationship between ABO blood group, von Willebrand factor and primary hemostasis. Blood. 2020;136(25):2864–74. DOI: 10.1182/blood.2020005843
12. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thrombosis Research. 1989;53(4):387–94. DOI: 10.1016/0049-3848(89)90317-4
13. Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Losche W et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica. 2008;93(1):137–40. DOI: 10.3324/haematol.11677
14. Thurman JM, Holers VM. The Central Role of the Alternative Complement Pathway in Human Disease. The Journal of Immunology. 2006;176(3):1305–10. DOI: 10.4049/jimmunol.176.3.1305
15. Turner NA, Moake J. Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis. PLoS ONE. 2013;8(3):e59372. DOI: 10.1371/journal.pone.0059372
16. Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic Microangiopathies and the Linkage between von Willebrand Factor and the Alternative Complement Pathway. Seminars in Thrombosis and Hemostasis. 2014;40(05):544–50. DOI: 10.1055/s-0034-1383547
17. Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? Journal of Clinical Apheresis. 2007;22(1):21–5. DOI: 10.1002/jca.20114
18. Réti M, Farkas P, Csuka D, Rázsó K, Schlammadinger Á, Udvardy ML et al. Complement activation in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2012;10(5):791–8. DOI: 10.1111/j.1538-7836.2012.04674.x
19. Boneu B, Abbal M, Barret A, Fournie A, Bierme R. Von Willebrand factor activity and thrombophilic states. A review. Pathologie-Biologie. 1976;24(Suppl):48–53. PMID: 796810
20. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thrombosis and Haemostasis. 2006;95(1):49–55. PMID: 16543961
21. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. Journal of Clinical Investigation. 1997;99(6):1351–60. DOI: 10.1172/JCI119294
22. Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. The Journal of Biological Chemistry. 1983;258(20):12238–42. PMID: 6313646
23. Frenette PS, Wagner DD. Adhesion Molecules. New England Journal of Medicine. 1996;334(23):1526–9. DOI: 10.1056/NEJM199606063342308
24. Frenette PS, Wagner DD. Adhesion Molecules – Blood Vessels and Blood Cells. New England Journal of Medicine. 1996;335(1):43–5. DOI: 10.1056/NEJM199607043350108
25. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84(7):2068–101. PMID: 7522621
26. Степанова Т.В., Иванов А.Н., Терешкина Е.В., Попыхова Е.В., Лагутина Д.Д. Маркеры эндотелиальной дисфункции: патогенетическая роль и диагностическое значение (обзор литературы). Клиническая лабораторная диагностика. 2019;64(1):34–41. DOI: 10.18821/0869-2084-2019-64-1-34-41
27. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. Journal of Thrombosis and Haemostasis. 2006;4(6):1186–93. DOI: 10.1111/j.1538-7836.2006.01949.x
28. Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. Journal of Clinical Investigation. 1996;97(2):493–500. DOI: 10.1172/JCI118440
29. Galbusera M, Zoja C, Donadelli R, Paris S, Morigi M, Benigni A et al. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. Blood. 1997;90(4):1558–64. PMID: 9269774
30. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM et al. Free Fatty Acid Impairment of Nitric Oxide Production in Endothelial Cells Is Mediated by IKKβ. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(5):989–94. DOI: 10.1161/01.ATV.0000160549.60980.a8
31. Van Galen KPM, Tuinenburg A, Smeets EM, Schutgens REG. Von Willebrand factor deficiency and atherosclerosis. Blood Reviews. 2012;26(5):189–96. DOI: 10.1016/j.blre.2012.05.002
32. Vora DK, Fang Z-T, Liva SM, Tyner TR, Parhami F, Watson AD et al. Induction of P-Selectin by Oxidized Lipoproteins: Separate Effects on Synthesis and Surface Expression. Circulation Research. 1997;80(6):810–8. DOI: 10.1161/01.RES.80.6.810
33. Fuster V, Bowie EJW, Lewis JC, Fass DN, Owen CA, Brown AL. Resistance to Arteriosclerosis in Pigs with von Willebrand’s Disease. Journal of Clinical Investigation. 1978;61(3):722–30. DOI: 10.1172/JCI108985
34. Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99(12):4486–93. DOI: 10.1182/blood.V99.12.4486
35. Methia N, André P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor–deficient mice. Blood. 2001;98(5):1424–8. DOI: 10.1182/blood.V98.5.1424
36. Qin F, Impeduglia T, Schaffer P, Dardik H. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: Preliminary studies. Journal of Vascular Surgery. 2003;37(2):433–9. DOI: 10.1067/mva.2003.63
37. Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWFdependent mechanism. Journal of Thrombosis and Haemostasis. 2014;12(2):255–60. DOI: 10.1111/jth.12456
38. Kageyama S, Yamamoto H, Yoshimoto R. Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(10):2303–8. DOI: 10.1161/01.ATV.20.10.2303
39. Doddapattar P, Dhanesha N, Chorawala MR, Tinsman C, Jain M, Nayak MK et al. Endothelial Cell–Derived Von Willebrand Factor, But Not Platelet-Derived, Promotes Atherosclerosis in Apolipoprotein E–Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38(3):520–8. DOI: 10.1161/ATVBAHA.117.309918
40. Federici AB, Mannucci PM, Fogato E, Ghidoni P, Matturri L. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thrombosis and Haemostasis. 1993;70(5):758–61. PMID: 8128431
41. Chung DW, Chen J, Ling M, Fu X, Blevins T, Parsons S et al. Highdensity lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood. 2016;127(5):637–45. DOI: 10.1182/blood-2014-09-599530
42. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective Study of Hemostatic Factors and Incidence of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96(4):1102–8. DOI: 10.1161/01.CIR.96.4.1102
43. Wang X, Zhao J, Zhang Y, Xue X, Yin J, Liao L et al. Kinetics of plasma von Willebrand factor in acute myocardial infarction patients: a meta-analysis. Oncotarget. 2017;8(52):90371–9. DOI: 10.18632/oncotarget.20091
44. Yan B, Wang Q, Du W, Zhai S, Gou C, Hu T et al. Elevated Plasma von Willebrand Factor Antigen and Activity Levels Are Associated With the Severity of Coronary Stenosis. Clinical and Applied Thrombosis/Hemostasis. 2020;26:107602961990055. DOI: 10.1177/1076029619900552
45. Kato Y, Iwata A, Futami M, Yamashita M, Imaizumi S, Kuwano T et al. Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins. Medicine. 2018;97(17):e0589. DOI: 10.1097/MD.0000000000010589
46. Fuchs I, Frossard M, Spiel A, Riedmüller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. Journal of Thrombosis and Haemostasis. 2006;4(12):2547–52. DOI: 10.1111/j.1538-7836.2006.02239.x
47. Villmann J-M, Burkhardt R, Teren A, Villmann T, Thiery J, Drogies T. Atherosclerosis, myocardial infarction and primary hemostasis: Impact of platelets, von Willebrand factor and soluble glycoprotein VI. Thrombosis Research. 2019;180:98–104. DOI: 10.1016/j.thromres.2019.06.014
48. Yamashita A, Asada Y, Sugimura H, Yamamoto H, Marutsuka K, Hatakeyama K et al. Contribution of von Willebrand Factor to Thrombus Formation on Neointima of Rabbit Stenotic Iliac Artery Under High Blood-Flow Velocity. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(6):1105–10. DOI: 10.1161/01.ATV.0000077206.35631.B2
49. Zahger D, Fishbein MC, Garfinkel LI, Shah PK, Forrester JS, Regnstrom J et al. VCL, an Antagonist of the Platelet GP1b Receptor, Markedly Inhibits Platelet Adhesion and Intimal Thickening After Balloon Injury in the Rat. Circulation. 1995;92(5):1269–73. DOI: 10.1161/01.CIR.92.5.1269
50. Matsuno H, Kozawa O, Niwa M, Uematsu T. Inhibition of von Willebrand Factor Binding to Platelet GP Ib by a Fractionated Aurintricarboxylic Acid Prevents Restenosis After Vascular Injury in Hamster Carotid Artery. Circulation. 1997;96(4):1299–304. DOI: 10.1161/01. CIR.96.4.1299
51. Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GYH et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen: Systematic review and meta-analysis of randomised placebo-controlled trials. Thrombosis and Haemostasis. 2016;115(03):520–32. DOI: 10.1160/th15-08-0620
Рецензия
При поддержке: Конфликт интересов не заявлен
Для цитирования:
Алексеева И.В., Уразгильдеева С.А. Функциональная гетерогенность фактора фон Виллебранда: патогенетическое значение и практические аспекты использования в кардиологии. Кардиология. 2022;62(7):54-60. https://doi.org/10.18087/cardio.2022.7.n1641
For citation:
Alekseeva I.V., Urazgildeeva S.A. Functional heterogeneity of the von Willebrand factor: pathogenetic significance and practical aspects of use in cardiology. Kardiologiia. 2022;62(7):54-60. (In Russ.) https://doi.org/10.18087/cardio.2022.7.n1641
Просмотров: 219
Послать статью по эл. почте 
Оставить комментарий 